Vascarta Announces NIH Phase I clinical study of VAS-101 in sickle cell disease begins

SUMMIT, N.J., Aug. 19, 2026 /PRNewswire/ -- A second proof of concept phase I clinical study of VAS-101 (Vasceptor®; topical curcumin gel) in sickle cell disease (SCD) is underway. It is entitled: A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of VAS-101 in...